Santhera Pharmaceuticals Holdings Ltd.
Santhera Pharmaceuticals Holdings.../ CH1276028821 /
SPHDF
22/02/2024 18:23:09
|
Diferencia
-
|
Volumen |
Bid- |
Ask- |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
11.7000USD
|
-
|
300 Volumen de negocios: 3,510 |
-Volumen de oferta: - |
-Tamaño/ Volumen/ Formato de Ask: - |
130.85 millonesUSD |
- |
- |
Descripción de negocio
Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development of treatments for neuro-ophthalmological, neuromuscular and pulmonary diseases that currently lack treatment options, such as Leber's hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (DMD), congenital muscular dystrophy (CMD) and cystic fibrosis (CF). Santhera's lead product Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein, Serbia and Israel for the treatment of Leber's hereditary optic neuropathy (LHON) and is currently commercialized in more than 20 countries. Santhera is currently conducting the Phase III SIDEROS trial with Raxone® in patients with Duchenne muscular dystrophy (DMD) in respiratory function decline. In collaboration with the U.S. National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone® in a third indication, primary progressive multiple sclerosis (PPMS), and another product – omigapil – for congenital muscular dystrophy (CMD), both also areas of high unmet medical need.
Consejo de gestión & Consejo de supervisión
CEO |
Dario Eklund |
Consejo de gestión |
Andrew Smith, Günther Metz, Oliver Strub, Stephanie Brown, Shabir Hasham |
Consejo de supervisión |
Thomas Meier, Patrick Vink, Philipp Gutzwiller |
Datos de la empresa
Nombre: |
Santhera Pharmaceuticals Holding AG |
Dirección: |
Hohenrainstraße 24,CH-4133 Pratteln |
Teléfono: |
+41-61-9068950 |
Fax: |
+41-61-9068951 |
E-mail: |
office@santhera.com
|
Internet: |
www.santhera.com |
Industria: |
Healthcare |
Sector: |
Pharmaceutical Industry |
Subsector: |
Pharmaceuticals |
Fin del año financiero: |
31/12 |
Acciones de libre circulación: |
87.30% |
Fecha de OPI: |
- |
Relación con inversores
Nombre: |
Eva Kalias |
IR teléfono: |
+41 61 906 89 26 |
IR-fax: |
- |
IR e-mail: |
eva.kalias@santhera.com
|
Calendario de la empresa
CW 22 | 28/05/2024
General Shareholder Meeting
|